Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system.

Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, Chan KY, Garrelds IM, Johnson KW, Danser AHJ, Villalón CM, MaassenVanDenBrink A.

Pain. 2020 Jan 22. doi: 10.1097/j.pain.0000000000001801. [Epub ahead of print]

PMID:
31977930
2.

Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.

Mulder IA, Rubio-Beltran E, Ibrahimi K, Dzyubachyk O, Khmelinskii A, Hoehn M, Terwindt GM, Wermer MJH, MaassenVanDenBrink A, van den Maagdenberg AMJM.

Stroke. 2020 Jan;51(1):300-307. doi: 10.1161/STROKEAHA.119.025176. Epub 2019 Dec 6.

PMID:
31805844
3.

Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.

Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, Edvinsson L.

Cephalalgia. 2019 Nov 1:333102419884943. doi: 10.1177/0333102419884943. [Epub ahead of print]

PMID:
31674221
4.

CGRP-targeted antibodies in difficult-to-treat migraine.

de Vries T, MaassenVanDenBrink A.

Nat Rev Neurol. 2019 Dec;15(12):688-689. doi: 10.1038/s41582-019-0275-0. No abstract available.

PMID:
31595083
5.

Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries.

Messlinger K, MaassenVanDenBrink A.

Cephalalgia. 2019 Dec;39(14):1731-1734. doi: 10.1177/0333102419877169. Epub 2019 Sep 16. No abstract available.

PMID:
31526030
6.

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJJC, Zanelli E, Meeus L, Danser AHJ, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A.

Br J Pharmacol. 2019 Dec;176(24):4681-4695. doi: 10.1111/bph.14832. Epub 2019 Nov 7.

7.

Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Dirven C, Danser AJ, Xu C, Snellman J, MaassenVanDenBrink A.

Cephalalgia. 2019 Dec;39(14):1735-1744. doi: 10.1177/0333102419863027. Epub 2019 Jul 8.

PMID:
31284729
8.

Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models.

Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AH, Edvinsson L, MaassenVanDenBrink A.

Cephalalgia. 2019 Oct;39(11):1421-1434. doi: 10.1177/0333102419851810. Epub 2019 May 19.

PMID:
31104506
9.

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

van Hoogstraten WS, MaassenVanDenBrink A.

J Headache Pain. 2019 May 16;20(1):54. doi: 10.1186/s10194-019-1007-y. Review.

10.

Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.

Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM, Chellman GJ, Balasubramanian G, Rubio-Beltran E, MaassenVanDenBrink A, Monticello TM.

Regul Toxicol Pharmacol. 2019 Aug;106:224-238. doi: 10.1016/j.yrtph.2019.05.013. Epub 2019 May 11. Review.

11.

Effects of two isometheptene enantiomers in isolated human blood vessels and rat middle meningeal artery - potential antimigraine efficacy.

Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, de Vries R, Dammers R, Bogers AJJC, van den Bogaerdt A, Daugherty BL, Danser AHJ, Villalón CM, MaassenVanDenBrink A.

J Headache Pain. 2019 May 3;20(1):47. doi: 10.1186/s10194-019-1003-2.

12.

Association of migraine with calcification in major vessel beds: The Rotterdam Study.

Wen KX, Ikram MA, Franco OH, Vernooij M, MaassenVanDenBrink A, Bos D, Kavousi M.

Cephalalgia. 2019 Jul;39(8):1041-1048. doi: 10.1177/0333102419843148. Epub 2019 Apr 8.

PMID:
30961370
13.

Functional Characterization of the Prejunctional Receptors Mediating the Inhibition by Ergotamine of the Rat Perivascular Sensory Peptidergic Drive.

González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, MaassenVanDenBrink A, Villalón CM.

ACS Chem Neurosci. 2019 Jul 17;10(7):3173-3182. doi: 10.1021/acschemneuro.8b00611. Epub 2019 Feb 13.

PMID:
30695640
14.

Correction to: Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, Lampl C, Lidegaard Ø, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Sandset PM, Martelletti P; European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

J Headache Pain. 2018 Sep 10;19(1):81. doi: 10.1186/s10194-018-0912-9.

15.

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH).

Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Gantenbein AR, Kurth T, Lampl C, Lidegaard Ø, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Paemeleire K, Sandset PM, Terwindt GM, Vetvik KG, Martelletti P; European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH).

J Headache Pain. 2018 Aug 31;19(1):76. doi: 10.1186/s10194-018-0896-5. Review.

16.

PACAP38 and PAC1 receptor blockade: a new target for headache?

Rubio-Beltrán E, Correnti E, Deen M, Kamm K, Kelderman T, Papetti L, Vigneri S, MaassenVanDenBrink A, Edvinsson L; European Headache Federation School of Advanced Studies (EHF-SAS).

J Headache Pain. 2018 Aug 7;19(1):64. doi: 10.1186/s10194-018-0893-8. Review.

17.

Female sex hormones in men with migraine.

van Oosterhout WPJ, Schoonman GG, van Zwet EW, Dekkers OM, Terwindt GM, MaassenVanDenBrink A, Ferrari MD.

Neurology. 2018 Jul 24;91(4):e374-e381. doi: 10.1212/WNL.0000000000005855. Epub 2018 Jun 27.

PMID:
29950439
18.

Current understanding of meningeal and cerebral vascular function underlying migraine headache.

Levy D, Labastida-Ramirez A, MaassenVanDenBrink A.

Cephalalgia. 2019 Nov;39(13):1606-1622. doi: 10.1177/0333102418771350. Epub 2018 Jun 21.

PMID:
29929378
19.

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors.

González-Hernández A, Lozano-Cuenca J, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM.

J Headache Pain. 2018 May 25;19(1):40. doi: 10.1186/s10194-018-0869-8.

20.

Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine.

Haanes KA, Labastida-Ramírez A, Chan KY, de Vries R, Shook B, Jackson P, Zhang J, Flores CM, Danser AHJ, Villalón CM, MaassenVanDenBrink A.

J Headache Pain. 2018 May 25;19(1):41. doi: 10.1186/s10194-018-0867-x.

21.

Protective effects of PACAP in ischemia.

Reglodi D, Vaczy A, Rubio-Beltran E, MaassenVanDenBrink A.

J Headache Pain. 2018 Mar 2;19(1):19. doi: 10.1186/s10194-018-0845-3. Review.

22.

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment.

MaassenVanDenBrink A, Terwindt GM, van den Maagdenberg AMJM.

Genome Med. 2018 Feb 22;10(1):10. doi: 10.1186/s13073-018-0524-7.

23.

Calcitonin-gene-related peptide pathway mAbs and migraine prevention.

Paemeleire K, MaassenVanDenBrink A.

Curr Opin Neurol. 2018 Jun;31(3):274-280. doi: 10.1097/WCO.0000000000000548. Review.

PMID:
29432219
24.

Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?

Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A.

Pharmacol Ther. 2018 Jun;186:88-97. doi: 10.1016/j.pharmthera.2018.01.005. Epub 2018 Jan 17. Review.

25.

Side effects associated with current and prospective antimigraine pharmacotherapies.

González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):25-41. doi: 10.1080/17425255.2018.1416097. Epub 2017 Dec 15. Review.

PMID:
29226741
26.

Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, Lampl C, Lidegaard Ø, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Sandset PM, Martelletti P; European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

J Headache Pain. 2017 Oct 30;18(1):108. doi: 10.1186/s10194-017-0815-1. Erratum in: J Headache Pain. 2018 Sep 10;19(1):81.

27.

Gender aspects of CGRP in migraine.

Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, MaassenVanDenBrink A.

Cephalalgia. 2019 Mar;39(3):435-444. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.

28.

The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats.

Rivera-Mancilla E, Avilés-Rosas VH, Manrique-Maldonado G, Altamirano-Espinoza AH, Villanueva-Castillo B, MaassenVanDenBrink A, Villalón CM.

J Headache Pain. 2017 Oct 11;18(1):104. doi: 10.1186/s10194-017-0812-4.

29.

Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice.

Chan KY, Labastida-Ramírez A, Ramírez-Rosas MB, Labruijere S, Garrelds IM, Danser AH, van den Maagdenberg AM, MaassenVanDenBrink A.

J Cereb Blood Flow Metab. 2019 Apr;39(4):718-729. doi: 10.1177/0271678X17725673. Epub 2017 Aug 9.

30.

Calcitonin Gene-Related Peptide Receptor Agonism: A Double-Edged Sword?

Danser AHJ, MaassenVanDenBrink A.

Circulation. 2017 Jul 25;136(4):384-387. doi: 10.1161/CIRCULATIONAHA.117.028955. No abstract available.

PMID:
28739811
31.

Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats.

Rubio-Beltrán E, Labastida-Ramírez A, Hernández-Abreu O, MaassenVanDenBrink A, Villalón CM.

Eur J Pharmacol. 2017 Oct 5;812:97-103. doi: 10.1016/j.ejphar.2017.07.020. Epub 2017 Jul 8.

PMID:
28694067
32.

Pharmacological analysis of the increases in heart rate and diastolic blood pressure produced by (S)-isometheptene and (R)-isometheptene in pithed rats.

Labastida-Ramírez A, Rubio-Beltrán E, Hernández-Abreu O, Daugherty BL, MaassenVanDenBrink A, Villalón CM.

J Headache Pain. 2017 Dec;18(1):52. doi: 10.1186/s10194-017-0761-y. Epub 2017 May 4.

33.

Migraine and cardiovascular disease in women.

Linstra KM, Ibrahimi K, Terwindt GM, Wermer MJ, MaassenVanDenBrink A.

Maturitas. 2017 Mar;97:28-31. doi: 10.1016/j.maturitas.2016.12.008. Epub 2016 Dec 22. Review.

PMID:
28159058
34.

The influence of migraine and female hormones on capsaicin-induced dermal blood flow.

Ibrahimi K, Vermeersch S, Frederiks P, Geldhof V, Draulans C, Buntinx L, Lesaffre E, MaassenVanDenBrink A, de Hoon J.

Cephalalgia. 2017 Oct;37(12):1164-1172. doi: 10.1177/0333102416668659. Epub 2016 Sep 28.

PMID:
27687880
35.

Wiping Out CGRP: Potential Cardiovascular Risks.

MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD.

Trends Pharmacol Sci. 2016 Sep;37(9):779-788. doi: 10.1016/j.tips.2016.06.002. Epub 2016 Jun 21. Review.

PMID:
27338837
36.

Comment on "A second trigeminal CGRP receptor: function and expression of the AMY1 receptor".

Haanes KA, Chan KY, MaassenVanDenBrink A.

Ann Clin Transl Neurol. 2016 Feb 26;3(4):307-8. doi: 10.1002/acn3.286. eCollection 2016 Apr. No abstract available.

37.

A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan.

Ibrahimi K, Danser A, Terwindt GM, van den Meiracker AH, MaassenVanDenBrink A.

Cephalalgia. 2017 Jan;37(1):94-98. doi: 10.1177/0333102416637833. Epub 2016 Sep 29.

PMID:
26951335
38.

Inhibitory effect of chronic oral treatment with fluoxetine on capsaicin-induced external carotid vasodilatation in anaesthetised dogs.

Muñoz-Islas E, González-Hernández A, Lozano-Cuenca J, Ramírez-Rosas MB, Medina-Santillán R, Centurión D, MaassenVanDenBrink A, Villalón CM.

Cephalalgia. 2015 Oct;35(12):1041-53. doi: 10.1177/0333102414566818. Epub 2015 Jan 21.

PMID:
25608878
39.

Reduced trigeminovascular cyclicity in patients with menstrually related migraine.

Ibrahimi K, van Oosterhout WP, van Dorp W, Danser AH, Garrelds IM, Kushner SA, Lesaffre EM, Terwindt GM, Ferrari MD, van den Meiracker AH, MaassenVanDenBrink A.

Neurology. 2015 Jan 13;84(2):125-31. doi: 10.1212/WNL.0000000000001142. Epub 2014 Dec 10.

PMID:
25503623
40.

A human capsaicin model to quantitatively assess salivary CGRP secretion.

van Oosterhout WP, Schoonman GG, Garrelds IM, Danser AH, Chan KY, Terwindt GM, Ferrari MD, MaassenVanDenBrink A.

Cephalalgia. 2015 Jul;35(8):675-82. doi: 10.1177/0333102414553824. Epub 2014 Nov 3.

PMID:
25366550
41.

Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein.

Labruijere S, Chan KY, de Vries R, van den Bogaerdt AJ, Dirven CM, Danser AJ, Kori SH, MaassenVanDenBrink A.

Cephalalgia. 2015 Feb;35(2):182-9. doi: 10.1177/0333102414544977. Epub 2014 Jul 30.

PMID:
25078720
42.

Glutamate receptor antagonists in the management of migraine.

Chan K, MaassenVanDenBrink A.

Drugs. 2014 Jul;74(11):1165-76. doi: 10.1007/s40265-014-0262-0. Review.

PMID:
25030431
43.

Migraine and perimenopause.

Ibrahimi K, Couturier EG, MaassenVanDenBrink A.

Maturitas. 2014 Aug;78(4):277-80. doi: 10.1016/j.maturitas.2014.05.018. Epub 2014 Jun 2. Review.

PMID:
24954701
44.

Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds.

Grände G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L.

J Headache Pain. 2014 Apr 23;15:22. doi: 10.1186/1129-2377-15-22.

45.

Methylation of migraine-related genes in different tissues of the rat.

Labruijere S, Stolk L, Verbiest M, de Vries R, Garrelds IM, Eilers PH, Danser AH, Uitterlinden AG, MaassenVanDenBrink A.

PLoS One. 2014 Mar 7;9(3):e87616. doi: 10.1371/journal.pone.0087616. eCollection 2014.

46.

Cranioselectivity of sumatriptan revisited: pronounced contractions to sumatriptan in small human isolated coronary artery.

Chan KY, Labruijere S, Ramírez Rosas MB, de Vries R, Garrelds IM, Danser AH, Villalón CM, van den Bogaerdt A, Dirven C, MaassenVanDenBrink A.

CNS Drugs. 2014 Mar;28(3):273-8. doi: 10.1007/s40263-013-0136-0.

PMID:
24430784
47.

Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead.

Ibrahimi K, Vermeersch S, Danser A, Villalón CM, van den Meiracker AH, de Hoon J, MaassenVanDenBrink A.

Cephalalgia. 2014 Jun;34(7):514-22. doi: 10.1177/0333102413517773. Epub 2014 Jan 3.

PMID:
24391116
48.

Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats.

Marichal-Cancino BA, Altamirano-Espinoza AH, Manrique-Maldonado G, MaassenVanDenBrink A, Villalón CM.

Basic Clin Pharmacol Toxicol. 2014 Mar;114(3):240-7. doi: 10.1111/bcpt.12152. Epub 2013 Nov 11.

49.

Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats.

Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, Ruiz-Salinas I, González-Hernández A, Maassenvandenbrink A, Villalón CM.

Eur J Pharmacol. 2013 Dec 5;721(1-3):168-77. doi: 10.1016/j.ejphar.2013.09.039. Epub 2013 Sep 25.

PMID:
24076186
50.

Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.

Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A.

Expert Opin Drug Discov. 2013 Nov;8(11):1309-23. doi: 10.1517/17460441.2013.826644. Epub 2013 Aug 21. Review.

PMID:
23962310

Supplemental Content

Loading ...
Support Center